CTNM – contineum therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Contineum Therapeutics, Inc. (NASDAQ: CTNM) is now covered by analysts at Jones Trading. They set a "buy" rating and a $23.00 price target on the stock.
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $25.00 price target on the stock.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its price target lowered by analysts at Robert W. Baird from $32.00 to $16.00. They now have an "outperform" rating on the stock.
Form 4 Contineum Therapeutics, For: Mar 14 Filed by: Miralles Gines Diego
Form 3 Contineum Therapeutics, For: Mar 14 Filed by: Miralles Gines Diego
Form 8-K Contineum Therapeutics, For: Mar 14
Form S-8 Contineum Therapeutics,
Form 10-K Contineum Therapeutics, For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.